Overall Success Rates: Approximately 13.8% of all drug development programs lead to approval, higher than earlier estimates of 10.4% and 9.6% from prior studies1.
Phase-Specific Success:
Phase I to Phase II: 52% success rate.
Phase II to Phase III: 28.9% success rate.
Phase III to NDA/BLA submission: 57.8% success rate.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable